Current Diabetes Reports

, Volume 9, Issue 5, pp 325–328 | Cite as

When is evidence of lack of harm enough? Has the rosiglitazone controversy ended?

Clinical Trials Report


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.PubMedCrossRefGoogle Scholar
  2. 2.
    Rosen CJ: The rosiglitazone story-lessons from an FDA advisory committee meeting. N Engl J Med 2007, 357:844–846.PubMedCrossRefGoogle Scholar
  3. 3.
    Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189–1195.PubMedCrossRefGoogle Scholar
  4. 4.
    Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007, 370:1129–1136.PubMedCrossRefGoogle Scholar
  5. 5.
    Diamond GA, Bax L, Kaul S: Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007, 147:578–581.PubMedGoogle Scholar
  6. 6.
    Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180–1188.PubMedCrossRefGoogle Scholar
  7. 7.
    Nesto RW, Bell D, Bonow RO, et al.: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004, 27:256–263.PubMedCrossRefGoogle Scholar
  8. 8.
    Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289.PubMedCrossRefGoogle Scholar
  9. 9.
    Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427–2443.PubMedCrossRefGoogle Scholar
  10. 10.
    Karalliedde J, Buckingham R, Starkie M, et al.: Effect of various diuretic treatments on rosiglitazone-induced fluid retention. 2006, J Am Soc Nephrol 17:3482–3490.PubMedCrossRefGoogle Scholar
  11. 11.
    The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545–2559.CrossRefGoogle Scholar
  12. 12.
    ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572.CrossRefGoogle Scholar
  13. 13.
    BARI 2D Study Group: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503–2515.CrossRefGoogle Scholar
  14. 14.
    Retnakaran R, Zinman B: Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet 2009, 373:2088–2090.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Diabetes and Hormone Center of ExcellenceUniversity of Virginia Health SystemCharlottesvilleUSA

Personalised recommendations